Ginkgo Bioworks Holdings Overview
Latest ROE for Ginkgo Bioworks Holdings: -69.19% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-69.19%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for DNA is -69.19%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Ginkgo Bioworks Holdings's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, DNA currently prints -69.19% for ROE, while the sector average sits near -100.59%. That is roughly 31.2% above the sector mean. Large gaps often invite a closer look at Ginkgo Bioworks Holdings's growth, margins, and balance sheet.
Return on Equity shows how effectively Ginkgo Bioworks Holdings converts resources into returns. At -69.19%, DNA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting DNA's ROE (-69.19%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Ginkgo Bioworks Holdings's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
